Results. Twenty-seven dialysis patients (68 ± 12 years) were treated with STS for a median (25th, 75th percentile) of 96 (54, 133) days. Seven patients (26%) suffered from proximaltype, and 20 patients (74%) from distal-type calciphylaxis. Fourteen patients (52%) showed a complete remission, five patients (19%) a partial remission and eight patients (30%) progression that resulted in amputation in four patients. During a median follow-up of 101 (79, 273) days, 14 patients died (52%). Non-survivors were older (P = 0.04), showed higher CRP values (P = 0.04), presented more frequently with proximal-type calciphylaxis (P = 0.03), had a higher disease severity score at diagnosis (P = 0.01), were treated more often with antibiotics (P = 0.01) and cinacalcet (P = 0.03) and had a lower remission rate during treatment (P = 0.004) than did survivors. The use of antibiotics and cinacalcet, disease severity at diagnosis and remission rates were found to be significant survival predictors in logistic regression analysis. Conclusions. Calciphylaxis remains a serious complication with high mortality. Early and consistent therapy including STS may help to improve the disease outcome.
I N T RO D U C T I O N
Calciphylaxis (or calcific uraemic arteriolopathy) is a rare but life-threatening complication in patients with end-stage renal disease (ESRD). The condition is characterized by painful skin lesions including indurated plaques, livedo reticularis and necrosis, progressing to penetrating ulcerations with secondary wound infection [1, 2] . Histopathologically, the pannicular small-and medium-sized arteries and arterioles typically show calcification of the media, intimal hyperplasia, endovascular fibrosis and intravascular thrombosis resulting in an obliterative vasculopathy causing the painful ischaemic skin lesions [3] .
The concise pathomechanisms are still unclear, but disturbances in parathyroid hormone (PTH) and mineral metabolism, hypercoagulability mechanisms, qualitative or quantitative alterations in inhibitors of extraosseous calcification and endothelial dysfunction with imbalanced redox mechanisms as well as inflammatory mechanisms have been proposed [2, 4, 5] . Based on these pathophysiological considerations, various therapeutic approaches have been suggested. Given the absence of prospective randomized controlled trials, most data stem from single case reports or case series. Despite an observed high 1-year mortality rate between 45 and 55% [3, 6] , no therapy of proven benefit exists so far for this rare disease with a recently estimated prevalence of ≤1% in dialysis patients [1] . Besides parathyroidectomy, the use of cinacalcet or bisphosphonates, discontinuation of vitamin D receptor activators or calciumcontaining phosphate binders and coumarins, hyperbaric oxygen therapy, meticulous wound care including surgical and biosurgical debridement, antibiotic and analgesic therapy, sodium thiosulphate (STS) has been shown to be efficacious in various case series [2, 3, [7] [8] [9] [10] [11] . The mode of action of STS is still unclear, but antioxidative, vasodilatory and calcium-solubilizing effects have been proposed [12] .
The aim of the present study was to determine the therapeutic response to a multi-modal and multi-interventional treatment regimen including the consistent use of STS and analyse the risk factors for mortality in an Austrian cohort of ESRD patients with calciphylaxis, all treated with STS.
M AT E R I A L S A N D M E T H O D S
Medical charts were reviewed to retrospectively collect demographic, clinical, laboratory and medication data on 27 calciphylaxis patients treated with STS at seven Austrian dialysis centres between June 2004 and November 2010. These data were collected for the time of diagnosis of calciphylaxis and the last known time (within 4 weeks) prior to the study end (death or end of follow-up with data censored on 30 November 2010). Pre-dialysis laboratory parameters included plasma levels of albumin-corrected calcium, total calcium, phosphorus, parathyroid hormone (PTH), alkaline phosphatase (AP), pH, creatinine, albumin, leucocytes, haemoglobin and C-reactive protein (CRP).
Patients were also assessed for relevant pre-existing co-morbidities [coronary artery disease (CAD): myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, coronary artery stenosis ≥50%; peripheral artery disease (PAD): significant ultrasound-or angiographically proven vascular stenosis, percutaneous transluminal angioplasty (PTA), peripheral bypass, amputation; heart failure: ejection fraction <55%; diabetes mellitus; hypertension; liver disease]. Hypertension was defined as currently being on antihypertensive therapy, or as monthly averaged pre-dialysis blood pressure >140/90 mmHg in the month before inclusion. Medication assessment included pre-existing therapy at the time of diagnosis of calciphylaxis [coumarins, heparin, vitamin D receptor activators (VDRA), phosphate binders, cinacalcet, erythropoiesis-stimulating agents (ESA), iron replacement] as well as co-therapy in addition to STS (vitamin K supplementation, prostaglandins, antibiotics, steroids, cinacalcet, VDRA cessation, coumarin cessation, phosphate binders and analgesics). Any other additional treatments for calciphylaxis were also reported.
Localization of the lesions and disease severity were evaluated according to a predefined staging system: the proximal type included lesions affecting the trunk, buttocks, face and extremities above the elbow and knee; the distal type lower and upper extremities below knee or elbow [1, 3] ; mild lesions were characterized by pain/ erythema/induration/plaque or livedo reticularis, moderate lesions by bullae/small ulcers or circumscribed necrosis, severe lesions by deep penetrating ulcers/large area necrosis or infection at the lesion site [13] .
Primary outcomes during follow-up were all-cause mortality, remission and amputation rate. Complete remission was defined as complete wound healing; partial remission was defined as an improvement in disease severity by at least one stage (severe to moderate or mild, moderate to mild) or cessation in progression; progression by deterioration by at least one stage (mild to moderate or severe, moderate to severe). A complete follow-up was available for all patients.
The causes of end-stage renal failure were as follows: diabetic nephropathy (n = 8), vascular nephropathy (n = 2), interstitial nephritis (n = 4), glomerulonephritis (n = 4), bilateral renal cell carcinoma (n = 2), unknown cause (n = 7).
This study was conducted adherent with the Helsinki Declaration of 1975, as revised in 2000. All patients alive at the time of data collection gave written informed consent. Statistical analyses were performed with SPSS 18.0 (SPSS, Chicago, IL).
Statistical methods

R E S U LT S
Baseline characteristics at the time of first diagnosis for all patients and stratified by survival status are given in Table 1 . During a median (25th, 75th percentile) follow-up of 101 (79, 273) days, 14 patients died (52%). The causes of death were sepsis (n = 5), heart failure (n = 5), ileus with suspected gastrointestinal calciphylaxis involvement (n = 2), cerebral haemorrhage (n = 1) and myocardial infarction (n = 1). Non-survivors were significantly older (71 ± 9 versus 62 ± 12 years, P = 0.04) and showed higher CRP values (6.9 ± 3.9 versus 3.9 ± 2.8 mg/ dL, P = 0.04), but did not differ in any other parameter when compared with survivors.
Calciphylaxis was diagnosed clinically in all patients (100%), and was additionally biopsy-proven in 14 patients (52%). At the time of first diagnosis, seven patients (26%) suffered from proximal-type, and 20 patients (74%) from distal-type calciphylaxis. Survivors presented significantly more frequently with distal-type calciphylaxis than did non-survivors (92 versus 57% distal type, 8 versus 43% proximal type, P = 0.04). Patients with distal-type calciphylaxis showed a higher survival rate than patients with proximal-type (60 versus 14%, P = 0.04). Mild lesions were found in three patients (11%), moderate lesions in six (22%) and severe lesions in 18 patients (67%) at the time of first diagnosis. Non-survivors presented with a significantly higher disease severity score at diagnosis (P = 0.01), as shown in Figure 1 .
The median (25th, 75th percentile) duration of STS treatment was 96 (54, 133) days. STS was started with a mean delay of 41 ± 61 days after diagnosis. Time delay between first diagnosis and initiation of STS treatment did not differ statistically between survivors and non-survivors (23 ± 23 versus 57 ± 78 days; P = 0.14), although treatment was started later in non-survivors. In 22 patients (81%), 25 g of STS was given intravenously three times per week, in four patients (15%) STS was given three times per week at a dose of 10 g and one patient received 25 g of STS intravenously five times per week. The mean cumulative STS dose for all patients was 1268 ± 1555 g [median (25th, 75th percentile) 875 (425, 1475) g]. STS was administered in the last hour of haemodialysis in 13 patients (48%), whereas it was given for 1 h after haemodialysis in 14 patients (52%). Generally, STS was well tolerated. In eight patients, the following 12 possibly STS-associated side effects were noted: nausea (n = 6), emesis (n = 1), dysgeusia (n = 1) and high anion-gap metabolic acidosis (n = 4). In 19 patients, no relevant STSassociated side effects were noted. All the above-mentioned patients with side effects received STS after haemodialysis, indicating a better tolerance when given during the last hour of haemodialysis. In addition to STS, the patients were treated with various adjunctive therapies, which are presented in detail in Table 2 .
As shown in Figure 2 , a complete remission was induced in 14 patients (52%), and a partial remission in 5 patients (19%), whereas 8 patients (30%) showed no response and progression that necessitated amputation in 4 patients. Survivors had a higher disease remission rate than did non-survivors (P = 0.004). Three patients showed complete remission of cutaneous lesions representing complete wound healing, but died because of heart failure (n = 1), septic pneumonia (n = 1) and ileus with suspected gastrointestinal calciphylaxis involvement (n = 1). These three patients reached the primary outcome all-cause mortality despite local therapeutic success. The timing of STS application did not influence remission rates. A partial or complete remission was found in nine patients (69%) with administration of STS during the last hour of haemodialysis and in 10 patients (71%) receiving STS for 1 h after the end of haemodialysis (P = 0.90). Diagnosis by a positive biopsy result was not associated with local response ( partial and complete remission, P = 0.21) or all-cause mortality (Tables 3 and 4) .
As shown in Table 3 , non-survivors were significantly older, presented with higher disease severity and suffered more frequently from proximal-type calciphylaxis at the time of diagnosis. They were treated more often with antibiotics and cinacalcet and had a lower remission rate during therapy than did survivors. More survivors received STS during the last hour of haemodialysis with borderline significance (P = 0.06). In a univariate logistic regression analysis, the need for antibiotic treatment and the use of cinacalcet were associated with a significantly poorer survival (Table 4) . A mild/ moderate disease severity at diagnosis (compared with severe) and a complete/partial remission (compared with no remission/progression) were associated with improved survival. The application of STS during the last hour of haemodialysis was also associated with a significant survival benefit (Table 4) .
D I S C U S S I O N
The present study retrospectively assessed the therapeutic response of dialysis patients with calciphylaxis to STS in a multi-interventional setting. The main findings were (i) a complete or partial disease remission rate of 70% using this strategy, (ii) sustained high mortality rate of 52% despite 
O R I G I N A L A R T I C L E S o d i u m t h i o s u l p h a t e a n d c a l c i p h y l a x i s
comprehensive use of available therapeutic options and consistent use of STS and (iii) disease severity and disease localization at the time of diagnosis as important survival predictors, emphasizing the need for early diagnosis and rapid initiation of therapy. Our multi-centre study in 27 patients is the largest study evaluating STS in dialysis patients with calciphylaxis reported to date. Except for the retrospective analysis by Noureddine et al. [13] with 14 patients, all other case reports or case series included seven patients or less [10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . With a nearly doubled patient number, we confirm the successful response rate of 70% to a multi-interventional therapy including STS found by Noureddine et al. [13] in terms of partial or complete remission. Nevertheless, 52% of our patients died during a median follow-up of 101 days despite the consistent use of STS. Thus, the prognosis for this rare disease remains poor despite multimodal therapy. This sustained high mortality is comparable with that reported in earlier publications [3, 6, 13, 24, 27] , although variable therapeutic regimens were used in those studies.
STS has been used for decades to treat cyanide intoxication and has also been successfully administered to prevent carboplatin-or cisplatin-induced oto-and nephrotoxicity [28, 29] . Yatzidis reported its efficacy for the treatment of recurrent calcium urolithiasis [30] . In 2004, Hyperbaric oxygen therapy, n (%) 1 (4) 0 (0) 1 (7) 1.00
Steroids, n (%) 2 (7) 1 (8) 1 (7) 1.00
Parathyroidectomy, n (%) 1 (4) 1 (8) Survivors versus Non-survivors b Phytomenadione (vitamin K 1 ) 10 mg iv 3x/week after haemodialysis (n = 5) or daily added to parenteral nutrition (n = 1), or oral phytomenadione (vitamin K 1 ) 5 mg daily (n = 3). VDRA, vitamin D receptor activator; Ca-P binder, calcium-containing phosphate binder.
F I G U R E 1 : Disease severity at diagnosis. Mild lesions were found in 3 patients (11%), moderate lesions in 6 (22%) and severe lesions in 18 patients (67%). Non-survivors had a higher disease severity score (P = 0.01).
STS was effectively used for the first time to treat calciphylaxis [10] . Several mechanisms have been put forward to explain its effect on calciphylaxis: originally, the proposed action was binding of calcium with the formation of highly soluble calcium thiosulphate complexes. The steady dissolution of calcium salts with subsequent elim- Time delay between the first diagnosis of calciphylaxis and the initiation of STS treatment. HD, haemodialysis. Data presented as mean ± SD or number (%).
Outcome (remission, amputation and survival rate). With STS, 14 patients (52%) showed a complete remission, 5 patients (19%) a partial remission, and 8 patients (30%) progression that resulted in amputation in 4 patients. During a median (25th, 75th percentile) follow-up of 101 (79, 273) days 14 patients (52%) died. Survivors had a higher remission rate upon therapy (P = 0.004).
ination via dialysis has been put forward to explain the slow removal of calcium deposits over weeks and months [2, 30, 31] . However, more recent studies suggest that STS prevents crystal formation and vascular calcification [32] [33] [34] and may also chelate iron, which has been implicated in the pathogenesis of calciphylaxis [4] . Additionally, STS exhibits antioxidative and vasodilating properties [11] . The latter effects may explain the higher therapeutic efficacy of STS when started early in the course of the disease, as shown in our study. Often reported and observed by ourselves, the rapid pain reduction might also be attributed to antioxidant and vasodilatory properties improving endothelial dysfunction [11, 12] . With a high percentage of women and a high body mass index, our study population was characterized by the typical known risk factors for calciphylaxis [3] . Patients with mild lesions had a better overall prognosis than did patients with advanced disease and severe lesions. Without STS, ulcerating calciphylaxis was found to be associated with an extremely high mortality when compared with mild or moderate lesions in earlier reports [6] , again emphasizing the need for early diagnosis and treatment. Furthermore, disease localization also seems to be an important predictor of therapeutic response to STS and survival. In our study, survivors more frequently presented with distal-type calciphylaxis (92 versus 57%, P = 0.04), and distal-type was associated with better survival in regression analysis with borderline significance (P = 0.06). Nevertheless, the mortality rate was still 40% (8/20 patients) even in patients with distal-type calciphylaxis in our study.
The higher proportion of patients treated with antibiotics and cinacalcet in the non-surviving group likely demonstrates a more progressive and severe course of disease leading to this therapy, rather than a negative influence of these drugs per se. Moreover, in non-surviving patients, the dialysis intensity was increased more often, and in a higher proportion of patients in this group, the dialysate calcium concentration was decreased. Nevertheless, this broad therapy may have been started too late in these patients. Although not statistically significant, non-survivors suffered more often from relevant co-morbidities including a higher percentage of patients with diabetes, CAD, PAD and heart failure. Therefore, one may speculate that in these patients, calciphylaxis took a more aggressive and ultimately fatal course. The higher prevalence of PAD in non-survivors may have caused a delay in instituting treatment for calciphylaxis, because treating physicians probably initially misinterpreted first signs as ischaemic lesions.
Coumarin therapy was discontinued in 75% of all patients after the diagnosis of calciphylaxis, with therapy cessation in all surviving patients, but only in 50% of nonsurvivors. As the extraosseous mineralization inhibitor matrix Gla protein (MGP) requires a vitamin K-dependent gamma-carboxylation step for activation, the use of vitamin K antagonists has been proposed as an additional risk factor for calciphylaxis [1, 12] . Therefore, based on this mechanism it is generally advocated that coumarins be stopped. Only in 41% of pre-treated patients were vitamin D receptor activators discontinued, and in 67% of pre-treated patients the use of calcium-based phosphate binders was stopped. These findings may be explained by the comparably low mean serum calcium (8.82 ± 0.84 mg/dL) and phosphorus (5.14 ± 1.77 mg/dL) levels with acceptable control of secondary hyperparathyroidism (PTH 362 ± 298 pg/mL), tempting some treating physicians to continue pre-existing chronic kidney disease-mineral and bone disorders therapy. Due to limited accessibility, hyperbaric oxygen therapy was administered in only one patient. Also, parathyroidectomy was performed in only one patient. This may be explained by the only moderate hyperparathyroidism. As shown by Mawad et al., not only severe hyperparathyroid bone disease but also adynamic bone disease can be associated with calciphylaxis [35] . Due to an abnormal calcium homeostasis with decreased skeletal calcium storage [36] , these patients may be at risk of vascular calcification. Therefore, bone biopsy-if feasible-may help to control therapy and to avoid PTH oversuppression in the case of low bone turnover. A surgical debridement was performed in six patients (22%). Possibly, the fear of iatrogenic induction of new lesions or aggravation of existing lesions through traumatic manipulation may explain the low rate of surgical intervention. This may also be the reason for reluctance to perform a diagnostic biopsy in about half of our patients. In accordance with the literature, the empirical dose of 25 g of STS given intravenously three times per week was used in most of our patients. Due to the retrospective and multi-centre study design, STS was not given uniformly to all patients, but in three various doses and at two different times (namely in the last hour of haemodialysis or for 1 h after haemodialysis), resulting in variable weekly doses. As shown by pharmacokinetic simulations, the effective mean weekly dose might have varied inter-individually [37] . Due to the high dialyser clearance of STS as a low-weight molecule, dose modifications may be necessary with varying dialysis intensity, modality and application time in order to guarantee adequate dosing and avoid toxicity as indicated by recent pharmacokinetic studies [38] . Our results also suggest that application of STS during the last hour of dialysis, when dialysate sodium and bicarbonate can be appropriately adapted to counteract the potential STS-induced sodium and acid load, avoids side effects and is, therefore, preferred to the application after dialysis. An additional survival benefit with the intradialytic application during the last hour of dialysis, as noted in our study, needs to be confirmed by larger studies. STS was initiated with a mean delay of 41 ± 61 days after diagnosis. This delay was more than twice as long in non-survivors as in survivors. Due to the multi-centre design, various clinical suspicion and disease knowledge may have caused the differing delays. Applying a standardized treatment protocol including the immediate use of STS right from the first day of diagnosis in a multi-interventional approach might have improved overall outcome. Such a successful single-centre experience was recently reported in seven patients [39] .
Several limitations of our study must be acknowledged. First, our retrospective approach without a control group does not allow a definite causal inference to be made. Second, STS was part of a multi-interventional approach including various other treatment options. Therefore, the specific positive effect of STS cannot be isolated. Nevertheless, using only a single therapeutic approach in this severe disease might be ethically unwarranted. Because of the rarity and high mortality of calciphylaxis, it seems unlikely that randomized controlled trials using STS solely will be performed in future. 
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